Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yeztugo
Fierce Biotech
Study finds HIV can evolve to resist lenacapavir—at a cost
After exposure to lenacapavir, HIV was able to shift the structure of its protein coating to avoid the drug’s effects.
Darren Incorvaia
Jan 7, 2026 2:00pm
Gilead's bictegravir, lenacapavir tablet meets mark in phase 3
Nov 13, 2025 9:55am
Gilead lifts guidance on PrEP launch despite cell therapy woes
Oct 31, 2025 11:51am
GSK touts study showing tolerability edge for its long-acting PrEP
Oct 15, 2025 8:45am
Gilead, Eisai, Vertex meds make Time's list of best inventions
Oct 10, 2025 11:58am
Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia
Sep 26, 2025 10:00am
